Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
Retrieved on:
Monday, January 9, 2023
WAKEFIELD, MA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BT BeaMedical Technologies (“BeaMed”), a private company minority-owned by Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) developing a next-generation laser based platform for epilepsy and cancer surgery, has notified the Company that it has entered into a definitive strategic agreement with Shina Systems Ltd. (“Shina”), a company specializing in medical imaging software platforms, in order to build on unique capabilities of Shina and accelerate the development, regulatory clearance, and commercial deployment of BeaMed’s StingRay Laser System for brain surgery.
Key Points:
- In addition, special software tools will be developed to leverage the unique laser-based surgical tools developed by BeaMed.
- Shina brings forward decades of relevant experience in rapid development and deployment of medical imaging software suites, including advanced CT/MRI imaging platforms for strategic health companies.
- “This agreement provides us with two key strategic advantages,” said Gil Shapira, Chief Executive Officer of BeaMed.
- Shina Systems Ltd. develops and markets clinical image management, PACS and medical imaging analysis application software for almost 3 decades.